IR@PKUHSC  > 北京大学临床肿瘤学院
学科主题临床医学
Dominant B cell epitope from NY-ESO-1 recognized by sera from a wide spectrum of cancer patients: Implications as a potential biomarker
Zeng, G; Aldridge, ME; Wang, Y; Pantuck, AJ; Wang, AY; Liu, YX; Han, Y; Yuan, YH; Robbins, PF; Dubinett, SM; DeKernion, JB; Belldegrun, AS
关键词SEREX tumor antigen immunotherapy tumor biomarker cancer vaccine
刊名INTERNATIONAL JOURNAL OF CANCER
2005-03-20
DOI10.1002/ijc.20716
114期:2页:268-273
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Oncology
研究领域[WOS]Oncology
关键词[WOS]HUMAN TUMOR-ANTIGENS ; IMMUNE-RESPONSES ; ANTIBODY ; PROTEIN ; IMMUNOTHERAPY ; EXPRESSION ; IDENTIFICATION ; TARGETS ; LAGE-1 ; PANEL
英文摘要

Monitoring the spontaneous antibody (Ab) response against a panel of relevant tumor-associated antigens (TAA) in cancer patients may provide useful information regarding the clinical status of cancer. However, current Ab detection approaches require the purification of recombinant proteins, which is often difficult to achieve. In order to bypass the purification of recombinant proteins, we identified a dominant B-cell epitope from a shared tumor antigen NY-ESO-1. A synthetic peptide of the epitope, ESO:1-40, was as sensitive as the recombinant protein for detecting Ab against NY-ESO-1 in most patients. NY-ESO-1 specific Ab present in the sera of patients with melanoma, prostate cancer, nonsmall cell lung cancer, esophageal cancer, gastric cancer and hepatocellular carcinoma reacted with the dominant peptide at a similar frequency as the recombinant protein. To our knowledge, ESO: 1-40 is the first peptide epitope recognized by sera from a wide spectrum of cancer patients but not healthy donors. This simple and straightforward approach may allow the investigation of the clinical significance of spontaneous Ab responses against multiple TAA and their correlation with the clinical course of malignant diseases in the future. (C) 2004 Wiley-Liss, Inc.

语种英语
WOS记录号WOS:000226734200016
引用统计
被引频次:29[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/65461
专题北京大学临床肿瘤学院
作者单位1.Univ Calif Los Angeles, David Geffen sCh Med, Hlth Sci Ctr, Dept Urol, Los Angeles, CA 90095 USA
2.Univ Calif Los Angeles, David Geffen sCh Med, Hlth Sci Ctr, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA
3.Univ Calif Los Angeles, Dept Med, Div Pulm & Crit Care Med, Los Angeles, CA 90095 USA
4.Peking Univ, Med Ctr, Beijing Canc Hosp, Beijing 100871, Peoples R China
5.Natl Canc Inst, Surg Branch, Bethesda, MD USA
推荐引用方式
GB/T 7714
Zeng, G,Aldridge, ME,Wang, Y,et al. Dominant B cell epitope from NY-ESO-1 recognized by sera from a wide spectrum of cancer patients: Implications as a potential biomarker[J]. INTERNATIONAL JOURNAL OF CANCER,2005,114(2):268-273.
APA Zeng, G.,Aldridge, ME.,Wang, Y.,Pantuck, AJ.,Wang, AY.,...&Belldegrun, AS.(2005).Dominant B cell epitope from NY-ESO-1 recognized by sera from a wide spectrum of cancer patients: Implications as a potential biomarker.INTERNATIONAL JOURNAL OF CANCER,114(2),268-273.
MLA Zeng, G,et al."Dominant B cell epitope from NY-ESO-1 recognized by sera from a wide spectrum of cancer patients: Implications as a potential biomarker".INTERNATIONAL JOURNAL OF CANCER 114.2(2005):268-273.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Zeng, G]的文章
[Aldridge, ME]的文章
[Wang, Y]的文章
百度学术
百度学术中相似的文章
[Zeng, G]的文章
[Aldridge, ME]的文章
[Wang, Y]的文章
必应学术
必应学术中相似的文章
[Zeng, G]的文章
[Aldridge, ME]的文章
[Wang, Y]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。